PRPOHealthcare · Diagnostics & ResearchTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 19 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Precipio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (83): Smaller than most of the companies we track.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PRPO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Nov 2020 | Maxim Group | Initiates | Buy | — |
| 22 Nov 2019 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRPO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Precipio, Inc. returned +50.6% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 56% of US stocks
Cheaper than 30% of US stocks
Cheaper than 98% of US stocks
Higher than 74% of US stocks
Higher than 62% of US stocks
Higher than 55% of US stocks
Higher than 25% of US stocks
Higher than 24% of US stocks
Higher than 36% of US stocks
Higher than 32% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Precipio, Inc. has a market value of $47.4M and an enterprise value of $47.9M.
Revenue in the twelve months to 30 June 2026: $27.2M. The latest quarter grew 24.2% year on year.
Net income over the same four quarters: −$1.2M, a −4.5% net margin.
Free cash flow in the twelve months to 30 June 2026: $789K.
Trailing P/E: −114.7×; forward P/E: 67.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Precipio, Inc. employs 61 people — $446K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Precipio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A Zacks Investment Research article compares Precipio and Biodesix, two cancer diagnostics companies with different approaches, examining which stock looks more compelling at this time.
Why it matters — A PRPO watcher would care because the piece directly evaluates Precipio against a peer in cancer diagnostics, offering a comparative view of the company.
Precipio reported second-quarter 2026 results showing strengthened revenue momentum, driven by higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation. The company's stock gained following the earnings announcement.
Why it matters — The report points to sustained revenue growth, record product sales, and improved profitability metrics, which indicate the company's momentum continued into its second quarter.
Precipio, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the event. The transcript covers the company's quarterly results and management commentary.
Why it matters — A PRPO watcher would care because the earnings call transcript provides direct insight into the company's quarterly performance and management's outlook.
Precipio announced its Q2-2026 financial results, reporting a quarterly record in revenue, a return to positive Adjusted EBITDA, and a strengthened cash position.
Why it matters — A return to positive Adjusted EBITDA and record revenue signal improved financial health for Precipio, which matters to PRPO watchers tracking the company's turnaround progress.
Precipio, Inc. announced it will host its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET. The call will provide a business update for the second quarter of 2026.
Why it matters — Shareholders and investors monitoring PRPO will want to listen to the call for the company's latest quarterly business performance and outlook.
Of the 1 analysts covering Precipio, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Precipio, Inc. 49 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Precipio, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).
No analyst covering Precipio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRPO are extrapolating price history, which says nothing about the business.
Precipio, Inc. returned +50.6% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Precipio Inc. is a healthcare biotechnology company focused on cancer diagnostics, with a particular emphasis on hematologic malignancies and laboratory error reduction.
The most recent item we track (Zacks Investment Research, 24 Aug 2026): "PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?". A Zacks Investment Research article compares Precipio and Biodesix, two cancer diagnostics companies with different approaches, examining which stock looks more compelling at this time.
Precipio Inc. is a healthcare biotechnology company focused on cancer diagnostics, with a particular emphasis on hematologic malignancies and laboratory error reduction. The company provides specialized diagnostic services for blood cancers and develops proprietary products used by pathology laboratories, including genetic panels, cell culture media, and related assay technologies. Its business is organized around diagnostic services and diagnostic products, creating an integrated platform that supports testing, workflow efficiency, and clinical decision-making. Precipio Inc. also serves biopharma customers through biomarker testing and clinical project services. Based in New Haven, Connecticut, the company operates in the clinical diagnostics and life sciences markets, where it aims to improve the accuracy and utility of cancer testing for physicians, laboratories, and patients.
CEO Mr. Ilan Danieli · 61 employees · United States · https://www.precipiodx.com
